Little evidence to support use of common antidepressant in autism
While the SSRI fluoxetine appeared to improve obsessive-compulsive behaviours at 16 weeks compared with placebo in children and adolescents with autism spectrum disorders (ASD) in the initial analysis, the difference between groups became nonsignificant after correcting for potential confounding factors and imbalances in baseline characteristics, reveals the FAB* study.